


The Unmet Need in Psoriasis:

Impact of Obesity on PsO Treatment Response

Despite advances in treatment, complete skin clearance remains an unmet need for many patients with PsO. The high prevalence of obesity in this population may play a significant role in suboptimal clinical outcomes.^{1,2}

1. Skin Clearance Gap

Patients With PsO May Struggle to Achieve Complete Skin Clearance Across All Therapies¹⁻³




~40%-60%

of patients with PsO **DO NOT** achieve complete skin clearance (PASI 100) despite *advanced biologic therapies*^a

2. Disease Escalates

Patients With PsO and Untreated Obesity Have an Increased Risk of PsA Development^{b-e, 4-6}

Risk of PsA Development in Patients With PsO and Obesity Versus PsO and Healthy Weight



Note: Both studies shown are cohort studies.

The American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) identifies obesity, metabolic syndrome, and PsO severity as comorbid/risk factors in patients with PsO and directs that they be screened for and managed in clinical care.⁷

3. Obesity Limits Skin Clearance

Obesity Is Associated With Incomplete Skin Clearance in Patients With PsO, Despite Biologic Treatment^{4,8-11}

Persistent Residual Inflammation^h is Linked to Clinical Consequences:



Continued Impact to
Quality of Life



Occurrence of
Treatment Resistanceⁱ





Greater Risk of
Treatment Discontinuation



Increased Risk of
Psoriatic Arthritis

4. Prevalence of Obesity

Prevalence of Obesity and Overweight in US Patients With and Without PsO¹



78.4% of patients with PsO and 73.4% without PsO had overweight or obesity in 2024

Of patients with PsO, 75.0% with obesity and 68.2% with overweight had ≥1 weight-related comorbidity

5. Long Term Consequence

Severe PsO Confers Cardiovascular Risks, Which Can Drive Premature Mortality²⁻⁴



Severe PsO confers the highest CV risk (vs. controls), including up to

- **3-fold** increased odds of myocardial infarction
- **60% higher** odds of stroke
- **40% higher** odds of CV-related mortality

Patients with severe PsO^a have a **reduced life expectancy**, dying **~5 years** earlier than expected



6. Comprehensive PsO Care

Addressing Obesity May Interrupt the Psoriatic March⁵⁻⁶



Disease Control

Complete skin clearance (PASI 100) represents optimal disease control, supporting interruption of psoriatic disease progression rather than partial response.



Systemic Impact

Addressing obesity or overweight alongside psoriasis treatment may reduce systemic immune activation, with potential benefit for cardiovascular and metabolic health.



Patient Outcomes

Complete clearance combined with weight reduction is associated with higher quality of life, greater satisfaction, and stronger long-term treatment adherence.

^aRequiring systemic therapy or phototherapy.

BMI=body mass index; CV=cardiovascular; PASI=psoriasis area and severity index; PASI 100=100% improvement in psoriasis area and severity index; PsO=psoriasis.

1. Armstrong AW et al. Poster presented at Maui Derm Hawaii. 2026. 2. Garshick MS, et al. *J Am Coll Cardiol*. 2021;77(13):1670-1680. 3. Gelfand JM, et al. *Arch Dermatol*. 2007;143(12):1493-1499.

4. Abuabara K, et al. *Br J Dermatol*. 2010;163(3):586-592. 5. Augustin M, et al. *Dermatol Ther (Heidelb)*. 2024;14(10). 6. Trovato E, et al. *Dermatol Ther (Heidelb)*. 2025;15(7):1941-1952.